Vascular factors in Alzheimer’s disease


The vascular factor in Alzheimer’s disease (AD), affecting its development and progression, is one of the most urgent problems of modern neuroangiology. The research investigates the characteristics of cerebral angioarchitectonics identified at different stages of AD. The research included 106 patients: 1) The Test Group—47 patients suffering from various stages of AD; 2) The Control Group—59 patients suffering from the most common lesions of the brain accompanied by neurodegenerative changes, the development of dementia and cognitive impairment, but not having AD. All the patients underwent: the testing of cognitive functions (MMSE), the determination of severity of dementia (CDR) and AD stages (TDR), computed tomography (CT), magnetic resonance imaging (MRI), scintigraphy of the brain (SG), rheoencephalography (REG), and cerebral multigated angiography (MUGA). Patients with AD different stages showed the following changes in angioarchitectonics and microcirculation: Absence of pronounced atherosclerotic lesions of intracranial vessels, reduction of the capillary bed in the temporal and temporo-parietal regions, development of multiple arteriovenous shunts in the same areas, early venous discharge, abnormal expansion of venous trunks that receive blood from arteriovenous shunts, venous congestion at the border of the frontal and parietal region, increased looping of intracranial arteries. Control Group patients had no combination of the abovementioned changes. These vascular changes are specific for AD and are in fact the vascular factor of this disease; they may also be called dyscirculatory angiopathy of Alzheimer’s type (DAAT). Patients suffering from other diseases that are accompanied by neurodegenerative changes in the brain, dementia and cognitive impairment do not have them.

Share and Cite:

Maksimovich, I. (2012) Vascular factors in Alzheimer’s disease. Health, 4, 735-742. doi: 10.4236/health.2012.429114.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Alzheimer’s Association (2011) Alzheimer’s disease facts and figures. H
[2] Alzheimer’s Association (2010) Alzheimer’s disease facts and figures. H
[3] Generation Alzheimer’s: The defining disease of the baby boomers. H
[4] Torack, R.M. (1979) Adult dementia: History, biopsy, pathology. Neurosurgery, 4, 434-442.
[5] Saykin, A.J. and Wishart, H.A. (2003) Mild cognitive impairment: Conceptual issues and structural and functional brain correlates. Seminars in clinical. Neuropsy- chiatry, 8, 12-30. H
[6] Shen, L., Fipri, H.A., Saykin, A.J. and West, J.D. (2009) Parametric surface modeling and registration for comparison of manual and automated segmentation of the hippocampus. Hippocampus, 19, 588-595. H
[7] Waldemar, G., Dubois, B., Emre, M., et al. (2007) Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology, 14, e1-e26. H
[8] Perrin, R.J., Craig-Schapiro, R., Morris, J.C., et al. (2011) Identification and validation of novelcerebrospinal fluid biomarkers for staging early Alzheimer’s disease. Public Library of Science One, 12, e16032.
[9] Trojanowski, J.Q., Vandeerstichele, H., Korecka, M., et al. (2010) Update on the biomarker core of the Alzheimer’s disease neuroimaging initiative subjects. Alzhei-mer’s & Dementia, 6, 230-238.
[10] Adriaase, A., Sanz-Arigita, E., Binnewijzend, M., et al. (2011) Molecular markers of Alzheimer’s disease pathology and their relationship with default mode network integrity. Alzheimer’s & Dementia, 7, S2-S3.
[11] Chételat, G., Villemagne, V.L., Pike K.E., Ellis, K.A., Ames, D., Masters, C.L. and Rowe, C.C. (2012) Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer’s disease. Neurodegenerative Diseases, 10, 141-144.
[12] Meyer, P.T., Hellwig, S., Amtage, F., et al. (2011) Dualbiomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. Journal of Nuclear Medicine, 52, 393-400. H
[13] Morel, F. (1950) An apparently dyshoric and topical angiopathy. Monatsschrift für Psychiatrie und Neurologie, 120, 352-357.
[14] Di Carlo, A., Baldereschi, M., Amaducci, L., et al. (2002) Incidence of dementia, Alzheimer’s disease, and vascular dementia in Italy. The ILSA study. Journal of the American Geriatrics Society, 50, 41-48. H's%20disease%2C%20and%20vascular%20dementia%20in%20Italy.%20The%20ILSA%20Study.
[15] Skoog, I., Kalaria, R.N. and Breteler, M.M. (1999) Vascular factors and Alzheimer disease. Alzheimer Disease and Associated Disorders, 13, 106-114. H
[16] Kalaria, R.N. (2002) Small vessel disease and Alzheimer’s dementia: Pathological considerations. Cerebrovascular Diseases, 13, 48-52. H
[17] Kalaria, R.N. (2003) Vascular factors in Alzheimer’s disease. International Psychogeriatrics, 15, 47-52. H
[18] Maksimovich, I.V. (2009) Changes in angioarchetectonics of brain at Alzheimer’s disease. The Neurologic Bulletin, 2, 9-14. H
[19] Maksimovich, I.V. (2010) Dyscirculatory angiopathy of the brain of Alzheimer’s type. Alzheimer’s & Dementia, 6, 34-35.
[20] Altman, R. and Rutledge, J.C. (2010) The vascular contribution to Alzheimer’s disease. Clinical Science, 119, 407-421. H
[21] Maksimovich, I.V. and Gotman, L.N. (2006) Method of complex radiation diagnostics at preclinical and clinical stages of Alzheimer’s disease. Russian Patent No. 2315559.
[22] Maksimovich, I.V., Gotman, L.N. and Masyuk, S.M. (2006) Method of determining dimensions of temporal brain lobes in patients suffering from Alzheimer’s disease. Russian Patent No. 2306102.
[23] Folstein, M.F.S., Folstein, S.E. and McHugh, P.R. (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198. H
[24] Morris, J.C. (1993) The clinical dementia rating (CDR): Current version and scoring rules. Neurology, 11, 2412- 2414.
[25] Maksimovich, I.V. (2012) The tomography dementia rating scale—Morphologicalli determined scale of Alzheimer’s disease stages. Journal of Alzheimer’s Disease, 8, 335-336.
[26] Maksimovich, I.V. (2011) Endovascular low-energy laser radiation effect on dyscirculatory angiopathy of Alzhei-mer’s type in the treatment of Alzheimer’s disease. Alzheimer’s & Dementia, 7, S791-S793.
[27] Maksimovich, I.V. (2011) Dyscirculatory angiopathy of Alzheimer’s type. Journal of Behavioral and Brain Science, 1, 57-68.
[28] Chen, W., Song, X., Beyea, S., D’Arcy, R. and Zhan, Y. (2011) Rockwood K advances in perfusion magnetic resonance imaging in Alzheimer’s disease. Alzheimer’s & Dementia, 7, 185-196.
[29] Rodriguez, G., Vitali, P., Calvini, P., Bordoni, C., Girtler, N., Taddei, G., Mariani, G. and Nobili, F. (2000) Hippo-campal perfusion in mild Alzheimer’s disease. Psychiatry Research, 100, 65-74.
[30] Hunter, J.M., Kwan, J., Malek-Ahmadi, M., Maarouf, C.L., Kokjohn, T.A., Belden, C., Sabbagh, M.N., Beach, T.G. and Roher, A.E. (2012) Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer’s disease. PLoS One, 7, e36893.
[31] Weller, R.O., Subash, M., Preston, S.D., Mazanti, I. and Carare, R.O. (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathology, 18, 253-266. H
[32] Zlokovic, B.V. (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience, 3, 723-738.'s%20disease%20and%20other%20disorders.%20
[33] Maksimovich, I.V. and Polyaev, Yu. A. (2010) The importance of early diagnosis of dyscircular angiopathy of Alzheimer’s type in the study of heredity of Alzheimer’s disease. Alzheimer’s & Dementia, 6, e43.
[34] Cameron, D.J., Galvin, C., Alkam, T., Sidhu, H., Ellison, J., Luna, S. and Ethell, D.W. (2012) Alzheimer’s related peptide amyloid-β plays a conserved role in angiogenesis. PLoS One, 7, e39598.'s-Rlated%20Peptide%20Amyloid-%CE%B2%20Plays%20a%20Conserved%20Role%20in%20Angiogenesis
[35] Chiang, G.C., Insel, Ph.S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S., Jack, C.R. and Weiner, M.W. (2011) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology, 259, 844-851. H
[36] Dickerson, B.C. (2006) Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment. Current Opinion in Psychiatry, 19, 299-306. H
[37] Tae, W.S., Kim, S.S., Lee, K.U., et al. (2008) Validation of hippocampal volumes measured usinga a manual method and two automated methods (free surfer and IBA-SPM) in chronic major depressive disorder. Neuroradiology, 50, 569-581.
[38] Burton, E.J., Barber, R., Mukaetova-Ladinska, E.B., Robson, J., Perry, R.H., Jaros, E., Kalaria, R.N. and O’Brien, T.J. (2009) Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: A prospective study with pathological verification of diagnosis. Brain, 132, 195-203.
[39] Hommet, C., Mondon, K., Constans, T., Beaufils, E., Desmidt, T., Camus, V. and Cottier, J.P. (2011) Review of cerebral microangiopathy and Alzheimer’s disease: Relation between white matter hyperintensities and micro-bleeds. Dementia and Geriatric Cognitive Disorders, 32, 367-378. H
[40] De la Torre, J.C. (2012) A turning point for Alzheimer’s disease? Biofactors, 38, 78-83. H's%20disease%3F

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.